The study, titled ‘Deficiency of protein kinase Cδ reprograms macrophage immunometabolism to suppress pyroptosis and stabilize atherosclerotic plaques,’ examines how removing this single kinase alters the metabolic machinery inside macrophages and, as a consequence, changes the inflammatory character of atherosclerotic lesions. The finding is notable because it links three areas that have usually been studied in isolation: kinase signaling, immunometabolism, and the inflammatory form of cell death known as pyroptosis. By connecting them, the work suggests that a pathway long associated with immune activation may instead be a liability in chronic vascular disease.

To understand why this matters, it helps to recall what macrophages do inside an artery wall. These cells are recruited to sites where low-density lipoprotein particles have accumulated beneath the endothelial lining. Once there, they engulf lipids, and in doing so they can become the foam cells that give early plaques their fatty appearance. But macrophages are not passive containers. They are metabolically active, decision-making cells whose internal fuel choices, whether to burn glucose rapidly through glycolysis, whether to rely on mitochondrial oxidative phosphorylation, whether to draw on fatty acid oxidation, shape the inflammatory signals they emit. A plaque dominated by pro-inflammatory macrophages tends to be rich in degradative enzymes and death signals, thinning its protective fibrous cap and raising the risk of rupture.

Pyroptosis is one of the most incendiary of those death signals. Unlike ordinary apoptosis, which quietly packages cellular debris for removal, pyroptosis is a lytic, inflammatory death driven by the activation of inflammasomes, multiprotein complexes that trigger caspase enzymes to cleave gasdermin proteins. Cleaved gasdermins form pores in the cell membrane, causing the cell to swell, burst, and spill its contents, including potent inflammatory messengers such as interleukin-1 family cytokines, into the surrounding tissue. Within a plaque, waves of pyroptotic macrophage death enlarge the necrotic core, weaken the fibrous cap, and promote the thrombus formation that turns a stable lesion into a clinical emergency.

Protein kinase C delta has long been recognized as a versatile signaling molecule in immune cells, participating in pathways that regulate activation, migration, and death decisions. The new research asked a direct question: what happens to macrophage behavior, and to atherosclerotic disease, when this kinase is missing? The answer, according to the study, is that deficiency of the kinase reprograms macrophage immunometabolism, shifting the internal metabolic set points of the cells in a direction that suppresses pyroptosis. In other words, without protein kinase C delta, macrophages appear to become less prone to the explosive inflammatory death that destabilizes plaques.

The concept of immunometabolic reprogramming is central to interpreting this result. Macrophages adopt broadly distinguishable metabolic profiles depending on their activation state, and these profiles are not merely byproducts of inflammation; they actively reinforce it. A glycolytic shift, for example, supports the rapid production of inflammatory mediators, while a more oxidative, mitochondrial-oriented metabolism tends to accompany reparative, tissue-tolerant behavior. By showing that removing protein kinase C delta rewrites these metabolic choices, the study positions the kinase as a kind of metabolic gatekeeper whose activity licenses the inflammatory, pyroptosis-prone phenotype in the plaque environment.

The downstream consequence reported in the work is plaque stabilization. In atherosclerosis research, stability is assessed through structural features: the thickness of the fibrous cap that separates the thrombogenic necrotic core from the bloodstream, the size of that necrotic core, the collagen content of the cap, and the burden of dead and dying cells within the lesion. A plaque that retains a thick cap, a modest necrotic core, and abundant collagen is far less likely to rupture than one riddled with pyroptotic debris. The finding that PKC delta deficiency suppresses pyroptosis and stabilizes plaques implies that the kinase contributes to precisely the features that make lesions dangerous, and that its removal tilts lesions toward a safer architecture.

These results arrive amid a broader reassessment of inflammation as a therapeutic target in cardiovascular medicine. Landmark clinical trials have already demonstrated that blunting inflammatory signaling, for instance through interleukin-1 beta blockade or colchicine treatment, reduces cardiovascular events in selected patients, validating the idea that the immune component of atherosclerosis is druggable. Against that backdrop, a kinase that governs whether plaque macrophages die inflammatory deaths is an attractive candidate for intervention, because it acts upstream of the terminal events, inflammasome activation, gasdermin pore formation, cytokine release, and necrotic core expansion, that directly damage plaque integrity.

At the same time, the study invites caution. Protein kinase C delta participates in many physiological processes beyond the plaque, including immune defense against infection, platelet function, and the regulation of cell survival in multiple tissues. Any therapeutic strategy aimed at inhibiting the kinase, or at exploiting the metabolic programs it controls, would need to weigh the benefit of calmer plaque macrophages against the risk of impairing the host responses that depend on this enzyme. Translating a reprogramming effect observed in experimental models into a safe clinical approach will require a detailed map of which downstream metabolic and inflammasome pathways mediate the protection, and whether those pathways can be targeted selectively.

Even so, the conceptual contribution is substantial. The work reframes atherosclerotic plaque stability not simply as a matter of lipid lowering, which remains the foundation of therapy, but as a matter of immune cell fate, decided by intracellular metabolic wiring that can be shifted by manipulating a single signaling node. If the findings hold up across models and, eventually, in human tissue, they suggest that future treatment could combine lipid management with agents that nudge plaque macrophages away from pyroptosis and toward a stable, reparative state. In a disease that kills millions each year largely through plaque rupture, teaching immune cells to keep their composure may prove to be one of the more consequential ideas in modern cardiovascular research.

Subject of Research: The role of protein kinase C delta deficiency in reprogramming macrophage immunometabolism to suppress pyroptosis and stabilize atherosclerotic plaques

Article Title: Deficiency of protein kinase Cδ reprograms macrophage immunometabolism to suppress pyroptosis and stabilize atherosclerotic plaques

Article References: Lien, C.-F., Chang, H.-Y., Yu, S.-H., Cho, R.-L., Chen, S.-J., Kuo, T.-T., Chong, P. C.-T., Ye, C.-H., Lin, F.-Y., Wu, W.-L., Lin, S.-H., Tsai, C.-S., & Lin, C.-S. (2026). Deficiency of protein kinase Cδ reprograms macrophage immunometabolism to suppress pyroptosis and stabilize atherosclerotic plaques. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01842-9

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01842-9

Keywords: protein kinase C delta, macrophages, immunometabolism, pyroptosis, atherosclerosis, plaque stability, inflammasome, foam cells, cardiovascular disease, inflammation, Deficiency, protein

Recent advances enabled researchers to meticulously scrutinize 613 non-synonymous single-nucleotide polymorphisms (nsSNPs) within the PKCδ gene, aiming to pinpoint variants capable of altering the enzyme’s structure and function in ways that predispose cells to malignancy. Non-synonymous variants change amino acids in the protein sequence, often with profound consequences on protein stability and interaction networks. Through a suite of sophisticated in silico tools and computational models incorporating sequence conservation and structural dynamics, this study sheds new light on how subtle genetic alterations may fuel breast cancer pathology.

Among the myriad nsSNPs analyzed, four mutations—V114G, C189R, C189Y, and W608R—stood out as highly oncogenic, disrupting PKCδ’s normal conformational integrity. Molecular dynamics simulations revealed that these substitutions provoke substantial deviations from the protein’s native architecture, increasing flexibility and potentially destabilizing key regions critical for enzymatic activity. Such disruptions are hypothesized to induce aberrant phosphorylation cascades underpinning tumorigenesis.

Of particular interest is the W608R variant, situated within the highly conserved AGC kinase domain, a region essential for PKCδ’s catalytic function. This mutation was shown to markedly distort the protein’s surface topology and alter its net charge, with potent repercussions for intramolecular and intermolecular interactions. Notably, disturbing PKCδ’s engagement with the signal transducer and activator of transcription 3 (STAT3) protein suggests a mechanism by which the variant might activate PKCδ through unconventional pathways, skirting traditional regulatory controls.

The implications of these findings extend beyond structural biology, as the study also established a robust epidemiological link between the W608R variant—denoted by the rs1703863535 SNP—and breast cancer risk. Individuals carrying the TT genotype exhibited an odds ratio (OR) of 2.7 and a relative risk (RR) of 1.6 for developing breast cancer, statistical indicators underscoring the variant’s potential as a biomarker for susceptibility and prognosis. This discovery opens new avenues for personalized medicine, wherein genetic screening could inform early detection and targeted interventions.

Moreover, the methodological framework employed in this research exemplifies the power of integrating computational genomics, structural bioinformatics, and molecular simulations to unravel the complexities of cancer biology. By delineating how specific genetic alterations influence the physical properties and interaction landscapes of crucial enzymes, scientists can better predict oncogenic potential and tailor therapeutic strategies accordingly.

The study further highlights the nuanced role of PKCδ in breast cancer. While overexpression of this kinase has been documented in tumor progression and poor patient outcomes, the precise molecular events enabling such pathogenic behavior were unclear. This investigation bridges that gap, elucidating how particular nsSNPs may confer functional changes that amplify PKCδ’s oncogenic potential, thereby promoting unchecked cell proliferation and metastasis.

Crucially, the research acknowledges the necessity of experimental validation beyond computational predictions. Functional assays in cellular and animal models will be vital to confirm the pathological mechanisms proposed and to explore avenues for pharmacological modulation of these variants. Nonetheless, the computational insights provided form an indispensable foundation on which such translational research can build.

The identification of rs1703863535 as a promising biomarker aligns with ongoing efforts to develop precision oncology tools. Biomarkers that accurately stratify patients based on genetic risk can revolutionize screening programs, enabling earlier interventions and optimizing therapeutic efficacy. This is particularly pertinent for breast cancer, one of the most common and deadly cancers among women worldwide.

Furthermore, understanding the interplay between PKCδ variants and signaling partners like STAT3 reveals potential targets for combination therapies. Inhibiting aberrant kinase activity or disrupting maladaptive protein-protein interactions may mitigate tumor aggressiveness and resistance to conventional treatments. The study’s findings lay groundwork for such innovative approaches.

By deploying computational methodologies capable of handling vast variant datasets, this research demonstrates a scalable pathway to identifying clinically meaningful genetic alterations across other oncogenes and tumor suppressors. The approach may be extrapolated to explore variant-driven disease mechanisms in diverse cancers and beyond.

In summary, this comprehensive analysis of PKCδ nsSNPs uncovers critical insights into the enzyme’s structural and functional perturbations associated with breast cancer. The discovery of the W608R variant’s oncogenic potential and epidemiological relevance accentuates the utility of integrating large-scale computational analyses with molecular biology to propel cancer biomarker discovery.

As researchers continue to unravel the genetic intricacies of cancer, studies such as this underscore the vital intersection of bioinformatics and molecular oncology. They serve as a testament to how cutting-edge computational science can illuminate pathways to personalized medicine and improved patient outcomes in the battle against breast cancer.

Subject of Research:
The study focuses on the identification and characterization of oncogenic non-synonymous single-nucleotide polymorphisms in the PKCδ enzyme and their functional implications in breast cancer pathology.

Article Title:
Comprehensive computational analysis of PKCδ non-synonymous variants identifies rs1703863535 as a potential breast cancer biomarker

Article References:
Zafar, S., Badshah, Y., Shabbir, M. et al. Comprehensive computational analysis of PKCδ non-synonymous variants identifies rs1703863535 as a potential breast cancer biomarker. BMC Cancer 25, 1667 (2025). https://doi.org/10.1186/s12885-025-15194-6

Image Credits:
Scienmag.com

DOI:
https://doi.org/10.1186/s12885-025-15194-6